Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 17/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 16/20 | 0.56 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4082526 | 0.91 | PTGER2 (0.49) | PTGER2PTGER4 | |
| SCHEMBL4077690 | 0.86 | PTGER2 (0.59) | PTGER2PTGER4 | |
| SCHEMBL4084920 | 0.86 | PTGER2 (0.49) | PTGER2PTGER4 | |
| SCHEMBL4082485 | 0.83 | PTGER2 (0.48) | PTGER2PTGER4 | |
| SCHEMBL4087585 | 0.81 | PTGER2 (0.59) | PTGER2PTGER4 | |
| SCHEMBL4090483 | 0.79 | PTGER2 (0.67) | PTGER2PTGER4 | |
| SCHEMBL1052742 | 0.78 | PTGER2 (0.54) | PTGER2PTGER4 | |
| SCHEMBL4082519 | 0.78 | PTGER4 (0.76) | PTGER2PTGER4 | |
| SCHEMBL30754098 | 0.77 | PTGER4 (0.48) | PTGER2PTGER4 | |
| SCHEMBL1056797 | 0.77 | PTGER2 (0.79) | PTGER2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | PTGER2 39/4885PTGER4 33/4885CCR5 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.